Identification of a selective glucocorticoid receptor modulator that prevents both diet-induced obesity and inflammation

British Journal of Pharmacology

Volumn 173, Issue 11, 2016, Pages 1793-1804

  Van Den Heuvel, José K ^a   Boon, Mariëtte R ^a   Van Hengel, Ingmar ^a   Peschier Van Der Put, Emma ^a   Van Beek, Lianne ^a   Van Harmelen, Vanessa ^a   Van Dijk, Ko Willems ^a   Pereira, Alberto M ^a   Hunt, Hazel ^b   Belanoff, Joseph K ^b   Rensen, Patrick C N ^a   Meijer, Onno C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Corcept Therapeutics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; CORTICOSTERONE; CORTICOTROPIN; FATTY ACID; GLUCOSE; HORMONE RECEPTOR AFFECTING AGENT; MESSENGER RNA; MIFEPRISTONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 1; GLUCOCORTICOID RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BROWN ADIPOSE TISSUE; CALORIC INTAKE; CONTROLLED STUDY; CYTOKINE RELEASE; DIET INDUCED OBESITY; ENERGY EXPENDITURE; FATTY ACID OXIDATION; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GONADAL FAT; IN VITRO STUDY; INFLAMMATION; LIPID DIET; LIPOLYSIS; MACROPHAGE MIGRATION INHIBITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAW 264.7 CELL LINE; WHITE ADIPOSE TISSUE; ANIMAL; BODY WEIGHT; C57BL MOUSE; DRUG EFFECTS; METABOLISM; OBESITY; PATHOLOGY;

ANIMALS; BODY WEIGHT; DIET, HIGH-FAT; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MIFEPRISTONE; OBESITY; RAW 264.7 CELLS; RECEPTORS, GLUCOCORTICOID;

EID: 84966359506     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13477     Document Type: Article

References (41)

1. Alexander SPH, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015). The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. Br J Pharmacol 172: 5956-5978.
2. Andrews RC, Walker BR, (1999). Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 96: 513-523.
3. Asagami T, Belanoff JK, Azuma J, Blasey CM, Clark RD, Tsao PS, (2011). selective glucocorticoid receptor (GR-II) antagonist reduces body weight gain in mice. J Nutr Metab 2011: 235389.
4. Auvinen HE, Coomans CP, Boon MR, Romijn JA, Biermasz NR, Meijer OC, et al., (2013). Glucocorticoid excess induces long-lasting changes in body composition in male C57Bl/6 J mice only with high-fat diet. Physiol Rep 1: e00103.
5. Beaudry JL, Dunford EC, Teich T, Zaharieva D, Hunt H, Belanoff JK, et al., (2014). Effects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset diabetes in young rats. PLoS One 9: e91248.
6. Berbee JF, Boon MR, Khedoe PP, Bartelt A, Schlein C, Worthmann A, et al., (2015). Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development. Nat Commun 6: 6356.
7. Berg AH, Scherer PE, (2005). Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96: 939-949.
8. Bligh EG, Dyer WJ, (1959). A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
9. Chakrabarti P, Kandror KV, (2009). FoxO1 controls insulin-dependent adipose triglyceride lipase (ATGL) expression and lipolysis in adipocytes. J Biol Chem 284: 13296-13300.
10. Clark RD, Ray NC, Williams K, Blaney P, Ward S, Crackett PH, et al., (2008). 1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity. Bioorg Med Chem Lett 18: 1312-1317.
11. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA, et al., (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461-3471.
12. Dallman MF, la Fleur SE, Pecoraro NC, Gomez F, Houshyar H, Akana SF, (2004). Minireview: glucocorticoids-food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology 145: 2633-2638.
13. De Bosscher K, Haegeman G, Elewaut D, (2010). Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 10: 497-504.
14. Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, Kanatani Y, et al., (2009). Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 58: 2574-2582.
15. Guillaume-Gentil C, Assimacopoulos-Jeannet F, Jeanrenaud B, (1993). Involvement of non-esterified fatty acid oxidation in glucocorticoid-induced peripheral insulin resistance in vivo in rats. Diabetologia 36: 899-906.
16. Havel PJ, Busch BL, Curry DL, Johnson PR, Dallman MF, Stern JS, (1996). Predominately glucocorticoid agonist actions of RU-486 in young specific-pathogen-free Zucker rats. Am J Physiol 271 (3 Pt 2): R710-R717.
17. Jung RT, Shetty PS, James WP, (1980). Heparin, free fatty acids and an increased metabolic demand for oxygen. Postgrad Med J 56: 330-332.
18. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group NCRRGW (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
19. Kohsaka A, Laposky AD, Ramsey KM, Estrada C, Joshu C, Kobayashi Y, et al., (2007). High-fat diet disrupts behavioral and molecular circadian rhythms in mice. Cell Metab 6: 414-421.
20. Lee MJ, Gong DW, Burkey BF, Fried SK, (2011). Pathways regulated by glucocorticoids in omental and subcutaneous human adipose tissues: a microarray study. Am J Physiol Endocrinol Metab 300: E571-E580.
21. Macfarlane DP, Forbes S, Walker BR, (2008). Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol 197: 189-204.
22. McGrath JC, Lilley E, (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189-3193.
23. Meijer OC, Kalkhoven E, van der Laan S, Steenbergen PJ, Houtman SH, Dijkmans TF, et al., (2005). Steroid receptor coactivator-1 splice variants differentially affect corticosteroid receptor signaling. Endocrinology 146: 1438-1448.
24. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, et al., (1985). Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61: 536-540.
25. Oosterman JE, Foppen E, van der Spek R, Fliers E, Kalsbeek A, la Fleur SE, (2014). Timing of fat and liquid sugar intake alters substrate oxidation and food efficiency in male Wistar rats. Chronobiol Int: 1-10.
26. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42: D1098-D1106.
27. Rodriguez AM, Palou A, (2004). The steroid RU486 induces UCP1 expression in brown adipocytes. Pflugers Arch 449: 170-174.
28. Schiffelers SL, Saris WH, van Baak MA, (2001). The effect of an increased free fatty acid concentration on thermogenesis and substrate oxidation in obese and lean men. Int J Obes Relat Metab Disord 25: 33-38.
29. Tempel DL, McEwen BS, Leibowitz SF, (1993). Adrenal steroid receptors in the PVN: studies with steroid antagonists in relation to macronutrient intake. Neuroendocrinology 57: 1106-1113.
30. Thaler JP, Yi CX, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO, et al., (2012). Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest 122: 153-162.
31. van den Beukel JC, Grefhorst A, Quarta C, Steenbergen J, Mastroberardino PG, Lombes M, et al., (2014). Direct activating effects of adrenocorticotropic hormone (ACTH) on brown adipose tissue are attenuated by corticosterone. FASEB J 28: 4857-4867.
32. van den Heuvel JK, Eggels L, van Rozen AJ, Luijendijk MC, Fliers E, Kalsbeek A, et al., (2014). Neuropeptide Y and leptin sensitivity is dependent on diet composition. J Neuroendocrinol 26: 377-385.
33. Van Klinken JB, van den Berg SA, Havekes LM, Willems Van Dijk K, (2012). Estimation of activity related energy expenditure and resting metabolic rate in freely moving mice from indirect calorimetry data. PLoS One 7: e36162.
34. Vandevyver S, Dejager L, Tuckermann J, Libert C, (2013). New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology 154: 993-1007.
35. Vroegrijk IO, van Klinken JB, van Diepen JA, van den Berg SA, Febbraio M, Steinbusch LK, et al., (2013). CD36 is important for adipocyte recruitment and affects lipolysis. Obesity (Silver Spring) 21: 2037-2045.
36. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, Furlow JD, et al., (2008). The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab 295: E785-E797.
37. Walker JJ, Spiga F, Gupta R, Zhao Z, Lightman SL, Terry JR, (2015). Rapid intra-adrenal feedback regulation of glucocorticoid synthesis. J R Soc Interface 12.20140875
38. Wang JC, Gray NE, Kuo T, Harris CA, (2012). Regulation of triglyceride metabolism by glucocorticoid receptor. Cell Biosci 2: 19.
39. Zalachoras I, Houtman R, Atucha E, Devos R, Tijssen AM, Hu P, et al., (2013). Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator. Proc Natl Acad Sci U S A 110: 7910-7915.
40. Zambon A, Hashimoto SI, Brunzell JD, (1993). Analysis of techniques to obtain plasma for measurement of levels of free fatty acids. J Lipid Res 34: 1021-1028.
41. Zhou J, Cidlowski JA, (2005). The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70: 407-417.